Protein adducts as prospective biomarkers of nevirapine toxicity

Chemical Research in Toxicology

Volumn 23, Issue 11, 2010, Pages 1714-1725

  Antunes, Alexandra M M ^a   Godinho, Ana L A ^a   Martins, Inês L ^a   Oliveira, M Conceição ^a   Gomes, Ricardo A ^b   Coelho, Ana V ^b   Beland, Frederick A ^c   Marques, M Matilde ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 MESYLOXY NEVIRAPINE; CYSTEINE; DRUG METABOLITE; HEMOGLOBIN; HISTIDINE; HUMAN SERUM ALBUMIN; LYSINE; NEVIRAPINE; SERINE; TRYPTOPHAN; UNCLASSIFIED DRUG; VALINE;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOLOGICAL MONITORING; COVALENT BOND; ELECTROSPRAY MASS SPECTROMETRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; TANDEM MASS SPECTROMETRY;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEMOGLOBINS; HIV INFECTIONS; HUMANS; MESYLATES; MOLECULAR SEQUENCE DATA; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SERUM ALBUMIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRYPTOPHAN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649281814     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx100186t     Document Type: Article

References (53)

1. FDA (1996) FDA approves nevirapine to treat HIV. News release T96-44, June 24, 1996.
2. Hammer, S. M., Eron, J. J., Jr., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., Jacobsen, D. M., Montaner, J. S. G., Richman, D. D., Yeni, P. G., and Volberding, P. A. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JAMA 300, 555-570
3. Perinatal HIV Guidelines Working Group (2009) Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, Apr 29, 2009, pp 1 - 90, http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf (accessed Apr 20, 2010).
4. Marseille, E., Kahn, J. G., Mmiro, F., Guay, L., Musoke, P., Fowler, M. G., and Jackson, J. B. (1999) Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa Lancet 354, 803-809
5. Jackson, J. B., Musoke, P., Fleming, T., Guay, L. A., Bagenda, D., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Owor, M., Ducar, C., Deseyve, M., Mwatha, A., Emel, L., Duefield, C., Mirochnick, M., Fowler, M. G., Mofenson, L., Miotti, P., Gigliotti, M., Bray, D., and Mmiro, F. (2003) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial Lancet 362, 859-868
6. Lallemant, M., Jourdain, G., Le Coeur, S., Mary, J. Y., Ngo-Giang-Huong, N., Koetsawang, S., Kanshana, S., McInstosh, K., and Thaineua, V., for the Perinatal HIV Prevention Trial (Thailand) Investigators (2004) Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351, 217 - 228
7. Lockman, S., Shapiro, R. L., Smeaton, L. M., Wester, C., Thior, I., Stevens, L., Chand, F., Makhema, J., Moffat, C., Asmelash, A., Ndase, P., Arimi, P., van Widenfelt, E., Mazhani, L., Novitsky, V., Lagakos, S., and Essex, M. (2007) Response to antiretroviral therapy after a single, peripartum dose of nevirapine N. Engl. J. Med. 356, 135-147
8. Lundgren, J. D., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W. G., Reiss, P., Sutinen, J., and Vigano, A., and the EACS Executive Committee (2008) European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 9, 72 - 81
9. Quinson, A., Arasteh, K., Plettenberg, A., Bogner, J., Boue, F., Livrozet, J. M., Witt, M., Van Steenberge, E., Sauce, C., Yong, C. L., Macha, S., Wu, J., Waldhauser, L., Mensa, F. J., Berger, F., Stern, J., Robinson, P., and Battegay, M. (2009) Steady state evaluation of two extended release (XR) nevirapine (NVP) tablets 400 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1 infected patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009), September 12-15, 2009, San Francisco, CA, paper #2879, http://www.hivandhepatitis.com/2009icr/icaac/pdfs/ quinson.pdf (accessed Apr 20, 2010).
10. Pollard, R. B., Robinson, P., and Dransfield, K. (1998) Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection Clin. Ther 20, 1071-1092
11. Mirochnick, M., Clarke, D. F., and Dorenbaum, A. (2000) Nevirapine: pharmacokinetic considerations in children and pregnant women Clin. Pharmacokinet. 39, 281-293
12. Waters, L., John, L., and Nelson, M. (2007) Non-nucleoside reverse transcriptase inhibitors: a review Int. J. Clin. Pract. 61, 105-118
13. VIRAMUNE® (nevirapine). Physicians' Desk Reference (2009) 63 rd ed, pp 873 - 881, Physicians' Desk Reference Inc., Montvale, NJ.
14. Powles, T., Robinson, D., Stebbing, J., Shamash, J., Nelson, M., Gazzard, B., Mandelia, S., Møller, H., and Bower, M. (2009) Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection J. Clin. Oncol. 27, 884-890
15. Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., and Sudo, K. (2008) Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity Drug Metab. Dispos. 36, 1770-1779
16. Riska, P., Lamson, M., MacGregor, T., Sabo, J., Hattox, S., Pav, J., and Keirns, J. (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans Drug. Metab. Dispos. 27, 895-901
17. Riska, P. S., Joseph, D. P., Dinallo, R. M., Davidson, W. C., Keirns, J. J., and Hattox, S. E. (1999) Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees Drug. Metab. Dispos. 27, 1434-1447
18. Erickson, D. A., Mather, G., Trager, W. F., Levy, R. H., and Keirns, J. J. (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450 Drug. Metab. Dispos. 27, 1488-1495
19. Liu, Z., Fan-Havard, P., Xie, Z., Ren, C., and Chan, K. K. (2007) A liquid chromatography/atmospheric pressure ionization tandem mass spectrometry quantitation method for nevirapine and its two oxidative metabolites, 2-hydroxynevirapine and nevirapine 4-carboxylic acid, and pharmacokinetics in baboons Rapid Commun. Mass Spectrom. 21, 2734-2742
20. Ren, C., Fan-Havard, P., Schlabritz-Loutsevitch, N., Ling, Y., Chan, K. K., and Liu, Z. (2010) A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons Biomed. Chromatogr. 24, 717-726
21. Silverman, R. B. (2004) The Organic Chemistry of Drug Design and Drug Action, 2 nd. ed., pp 1 - 617, Elsevier Academic Press, London, U.K.
22. Chen, J., Mannargudi, B. M., Xu, L., and Uetrecht, J. (2008) Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash Chem. Res. Toxicol. 21, 1862-1870
23. Shenton, J. M., Teranishi, M., Abu-Asab, M. S., Yager, J. A., and Uetrecht, J. P. (2003) Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat Chem. Res. Toxicol. 16, 1078-1089
24. Shenton, J. M., Popovic, M., Chen, J., Masson, M. J., and Uetrecht, J. P. (2005) Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat Chem. Res. Toxicol. 18, 1799-1813
25. Popovic, M., Caswell, J. L., Mannargudi, B., Shenton, J. M., and Uetrecht, J. P. (2006) Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats Chem. Res. Toxicol. 19, 1205-1214
26. Wen, B., Chen, Y., and Fitch, W. L. (2009) Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4 Drug Metab. Dispos. 37, 1557-1562
27. Srivastava, A., Lian, L.-Y., Maggs, J. L., Chaponda, M., Pirmohamed, M., Williams, D. P., and Park, B. K. (2010) Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries Drug Metab. Dispos. 38, 122-132
28. Meisheri, K. D., Johnson, G. A., and Puddington, L. (1993) Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil Biochem. Pharmacol. 45, 271-279
29. Merk, H. F. (2009) Drug skin metabolites and allergic drug reactions Curr. Opin. Allergy Clin. Immunol. 9, 311-315
30. Uetrecht, J. (2007) Idiosyncratic drug reactions: current understanding Annu. Rev. Pharmacol. Toxicol. 47, 513-539
31. Liebler, D. C. (2008) Protein damage by reactive electrophiles: targets and consequences Chem. Res. Toxicol. 21, 117-128
32. Aleksic, M., Thain, E., Roger, D., Saib, O., Davies, M., Li, J., Aptula, A., and Zazzeroni, R. (2009) Reactivity profiling: covalent modification of single nucleophile peptides for skin sensitization risk assessment Toxicol. Sci. 108, 401-411
33. Divkovic, M., Pease, C. K., Gerberick, G. F., and Basketter, D. A. (2005) Hapten-protein binding: from theory to practical application in the in vitro prediction of skin sensitization Contact Dermatitis 53, 189-200
34. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2005) The role of metabolic activation in drug-induced hepatotoxicity Annu. Rev. Pharmacol. Toxicol. 45, 177-202
35. Zhou, S., Chan, E., Duan, W., Huang, M., and Chen, Y.-Z. (2005) Drug bioactivation covalent binding to target proteins and toxicity relevance Drug Metab. Rev. 37, 41-213
36. Baillie, T. A. (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology Chem. Res. Toxicol. 19, 889-893
37. Angerer, J., Ewers, U., and Wilhelm, M. (2007) Human biomonitoring: state of the art Int. J. Hyg. Environ. Health 210, 201-228
38. Törnqvist, M., Fred, C., Haglund, J., Helleberg, H., Paulsson, B., and Rydberg, P. (2002) Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications J. Chromatogr., B 778, 279-308
39. Rubino, F. M., Pitton, M., Di Fabio, D., and Colombi, A. (2009) Toward an "omic" physiopathology of reactive chemicals: thirty years of mass spectrometric study of the protein adducts with endogenous and xenobiotic compounds Mass Spectrom. Rev. 28, 725-784
40. Antunes, A. M. M., Duarte, M. P., Santos, P. P., Gamboa da Costa, G., Heinze, T. M., Beland, F. A., and Marques, M. M. (2008) Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine Chem. Res. Toxicol. 21, 1443-1456
41. Antunes, A. M. M., Godinho, A. L. A., Martins, I. L., Justino, G. C., Beland, F. A., and Marques, M. M. (2010) Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine-a possible factor in nevirapine toxicity Chem. Res. Toxicol. 23, 888-899
42. Perrin, D. D. and Armarego, W. L. F. (1988) Purification of Laboratory Chemicals, 3 rd ed., pp 1 - 391, Pergamon Press, Oxford, U.K.
43. Törnqvist, M. (1994) Epoxide adducts to N-terminal valine of hemoglobin Methods Enzymol. 231, 650-657
44. Chevolleau, S., Jacques, C., Canlet, C., Tulliez, J., and Debrauwer, L. (2007) Analysis of hemoglobin adducts of acrylamide and glycidamide by liquid chromatography-electrospray ionization tandem mass spectrometry, as exposure biomarkers in French population J. Chromatogr., A 1167, 125-134
45. Neuhoff, V., Arold, N., Taube, D., and Ehrhardt, W. (1988) Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250 Electrophoresis 9, 255-262
46. Gomes, R. A., Oliveira, L. M. A., Silva, M., Ascenso, C., Quintas, A., Costa, G., Coelho, A. V., Sousa Silva, M., Ferreira, A. E. N., Ponces Freire, A., and Cordeiro, C. (2008) Protein glycation in vivo: functional and structural effects on yeast enolase Biochem. J. 416, 317-26
47. Tsao, M. and Otter, D. E. (1999) Quantification of glutamine in proteins and peptides using enzymatic hydrolysis and reverse-phase high-performance liquid chromatography Anal. Biochem. 269, 143-148
48. Baxter, J. H., Lai, C.-S., Phillips, R. R., Dowlati, L., Chio, J. J., Luebbers, S. T., Dimler, S. R., and Johns, P. W. (2007) Direct determination of methionine sulfoxide in milk proteins by enzyme hydrolysis/high-performance liquid chromatography J. Chromatogr., A 1157, 10-16
49. PeptideMass, Expasy, http://www.expasy.ch/tools/peptide-mass.html.
50. Rothschild, M. A., Oratz, M., and Schreiber, S. S. (1972) Albumin synthesis N. Engl. J. Med. 286, 748-757
51. Minghetti, P. P., Ruffner, D. E., Kuang, W.-J., Dennison, O. E., Hawkins, J. W., Beattie, W. G., and Dugaiczyk, A. (1986) Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4 J. Biol. Chem. 261, 6747-6757
52. Tannenbaum, S. R., Skipper, P. L., Wishnok, J. S., Stillwell, W. G., Day, B. W., and Taghizadeh, K. (1993) Characterization of various classes of protein adducts Environ. Health Perspect. 99, 51-55
53. Stewart, A. J., Blindauer, C. A., Berezenko, S., Sleep, D., Tooth, D., and Sadler, P. J. (2005) Role of Tyr84 in controlling the reactivity of Cys34 of human albumin FEBS J. 272, 353-362